Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A
Stock Exchange Frankfurt Stock Exchange
EPS
EUR1.67
Market Cap
EUR1.46 B
Shares Outstanding
139.18 M
Public Float
81.38 M
Ironwood Pharmaceuticals Inc. Cl A
Stock Exchange NASDAQ Stock Market
EPS
$1.94
Market Cap
$1.63 B
Shares Outstanding
155.62 M
Public Float
150.02 M

Profile

Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.

Financials

View All

Peter M. Hecht
Chief Executive Officer & Director
Terrance G. McGuire
Chairman